Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

Cancer

Volumn 121, Issue 9, 2015, Pages 1463-1468

  Vaughn, David J ^a   Hwang, Wei Ting ^a,b   Lal, Priti ^a,b   Rosen, Mark A ^a   Gallagher, Maryann ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cyclin dependent kinase inhibitor; germ cell tumor; palbociclib; PD0332991; teratoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PALBOCICLIB; RETINOBLASTOMA PROTEIN; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MALIGNANT TRANSFORMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TERATOMA; TERATOMA WITH MALIGNANT TRANSFORMATION; THROMBOCYTOPENIA; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PIPERAZINES; PYRIDINES; RETINOBLASTOMA PROTEIN; TERATOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928277686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29213     Document Type: Article

References (21)

1. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ., Medical treatment of advanced testicular cancer. JAMA. 2008; 299: 672-684.
2. Feldman DR, Patil S, Trinos MJ, et al. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2010; 118: 981-986.
3. Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer. 1982; 50: 1629-1635.
4. Necchi A, Colecchia M, Nicolai N, et al. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU Int. 2011; 107: 1088-1094.
5. Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 2003; 21: 4285-4291.
6. Harbour JW, Luo RX, Dei SA, Postigo AA, Dean DC., Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999; 98: 859-869.
7. Hall M, Peters G., Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996; 68: 67-108.
8. Toogood PL, Harvey PJ, Keller PR, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005; 48: 2388-2406.
9. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004; 3: 1427-1438.
10. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012; 18: 568-576.
11. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011; 104: 1862-8186.
12. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012; 119: 4597-4607.
13. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013; 31: 2024-2028.
14. Schmidt BA, Rose A, Steinhoff C, et al. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res. 2001; 61: 4214-4221.
15. Noel EE, Yesta-Velasco M, Mao X, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010; 176: 2607-2615.
16. Strohmeyere T, Reissmann P, Cordon-Cardo C, et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci U S A. 1991; 88: 6662-6666.
17. Bartkova J, Lukas C, Sorensen CS, et al. Deregulation of the RB pathway in human testicular germ cell tumours. J Pathol. 2003; 200: 149-156.
18. Vaughn DJ, Flaherty K, Lal P, et al. Treatment of growing teratoma syndrome. N Engl J Med. 2009; 360: 423-424.
19. Simon R., Optimal 2-stage design for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
20. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995; 13: 1170-1176.
21. Speiss PE, Kassouf W, Brown GA, et al. Surgical management of growing teratoma syndrome: the MD Anderson Cancer Center experience. J Urol. 2007; 177: 1330-1334.